Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| QYLD | XBI | |
|---|---|---|
Market Cap | $8.49B | $10.11B |
Volume | 2,913,938 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $18.68 | $169.55 |
52-Week Low | $16.70 | $104.99 |
Typical Hold Time | 51 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains a consistent monthly dividend payout of $0.18, providing an attractive yield for income-focused investors. Technical indicators present a mixed picture with an overall bullish signal from moving averages but bearish momentum from oscillators, while RSI levels suggest potential overbought conditions. Recent news highlights QYLD's role as a covered call ETF generating income through Nasdaq 100 options strategies.
The outlook for QYLD remains focused on income generation rather than capital appreciation, with the covered call strategy capping upside potential during market rallies. Key risks include declining option premiums, principal erosion over time, and tax treatment uncertainties. Investors should weigh the high monthly yield against the trade-off of limited participation in Nasdaq 100 growth, making it suitable for income needs but less ideal for long-term capital growth objectives.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
